NCT03020784View on ClinicalTrials.gov

Safety and Tolerability of PF-06818883 in Healthy Subjects

PHASE1TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 11, 2016

Primary Completion Date

June 13, 2017

Study Completion Date

June 13, 2017

Conditions
Healthy
Interventions
DRUG

Placebo

Placebo

DRUG

PF-06818883

Treatment

Trial Locations (1)

06511

Pfizer New Haven Clinical Research Unit, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03020784 - Safety and Tolerability of PF-06818883 in Healthy Subjects | Biotech Hunter | Biotech Hunter